{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:33:06Z","timestamp":1773145986929,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.ijpharm.2006.10.039","type":"journal-article","created":{"date-parts":[[2006,11,14]],"date-time":"2006-11-14T15:22:02Z","timestamp":1163517722000},"page":"1-11","source":"Crossref","is-referenced-by-count":67,"title":["Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC\u2013MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC\u2013MS"],"prefix":"10.1016","volume":"335","author":[{"given":"Li","family":"Di","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward H.","family":"Kerns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan Q.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy T.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2006.10.039_bib1","first-page":"30","article-title":"Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s","volume":"29","author":"Bapiro","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib2","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.31.7.815","article-title":"The conduct of in vitro and in vivo drug\u2013drug interaction studies: a pharmaceutical and manufacturers of America (PhRMA) perspective","volume":"31","author":"Bjornsson","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib3","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/1097-0231(20001030)14:20<1943::AID-RCM116>3.0.CO;2-F","article-title":"High-throughput cytochrome P450 inhibition screening via cassette probe-dosing strategy. IV. Validation of a direct injection on-line guard cartridge extraction\/tandem mass spectrometry method for simultaneous CYP3A4, 2D6 and 2E1 inhibition assessment","volume":"14","author":"Bu","year":"2000","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1124\/dmd.31.8.1005","article-title":"In vitro drug interactions of cytochrome P450: an evaluation of fluorogenic to conventional substrates","volume":"31","author":"Cohen","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib5","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1006\/abio.1997.2145","article-title":"Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450","volume":"248","author":"Crespi","year":"1997","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib6","first-page":"457","article-title":"High throughput screening for inhibition of cytochrome P450 metabolism","volume":"8","author":"Crespi","year":"1998","journal-title":"Med. Chem. Rev."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib7","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1367-5931(03)00055-3","article-title":"Profiling drug-like properties in discovery research","volume":"7","author":"Di","year":"2003","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/1087057103255988","article-title":"Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates","volume":"8","author":"Di","year":"2003","journal-title":"J. Biomol. Screen"},{"key":"10.1016\/j.ijpharm.2006.10.039_bib9","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/jps.20076","article-title":"Experimental design on single-time-point high-throughput microsomal stability assay","volume":"93","author":"Di","year":"2004","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ijpharm.2006.03.007","article-title":"High throughput microsomal stability assay for insoluble compounds","volume":"317","author":"Di","year":"2006","journal-title":"Int. J. Pharmaceut."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib11","first-page":"23","article-title":"A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry","volume":"29","author":"Dierks","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib12","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0090-9556(24)15203-8","article-title":"Improved reliability of the rapid microtiter plate assay using recombinant enzyme in predicting CYP2D6 inhibition in human liver microsomes","volume":"27","author":"Favreau","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib13","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1124\/jpet.104.082826","article-title":"CYP3A4 substrate selection and substitution in the prediction of potential drug\u2013drug interactions","volume":"314","author":"Galetin","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/108705710200700410","article-title":"Optimizing higher throughput methods to assess drug\u2013drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC50","volume":"7","author":"Gao","year":"2002","journal-title":"J. Biomol. Screen"},{"key":"10.1016\/j.ijpharm.2006.10.039_bib15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0090-9556(24)15274-9","article-title":"Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression","volume":"27","author":"Gibbs","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib16","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1177\/00912709922011764","article-title":"Assessment of the quality and quantity of drug\u2013drug interaction studies in recent NDA submissions: study design and data analysis issues","volume":"39","author":"Huang","year":"1999","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib17","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jpba.2003.08.001","article-title":"Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries","volume":"34","author":"Jenkins","year":"2004","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cbpa.2004.04.015","article-title":"Applications of high-throughput ADME in drug discovery","volume":"8","author":"Kassel","year":"2004","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib19","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1365-2125.1999.00073.x","article-title":"CYP3A4 drug interactions: correlation of 10 in vitro probe substrates","volume":"48","author":"Kenworthy","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S1359-6446(03)02649-7","article-title":"Pharmaceutical profiling in drug discovery","volume":"8","author":"Kerns","year":"2003","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ijpharm.2006.10.039_bib21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1359-6446(01)01712-3","article-title":"Screening for human ADME\/Tox drug properties in drug discovery","volume":"6","author":"Li","year":"2001","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ijpharm.2006.10.039_bib22","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1124\/dmd.31.5.606","article-title":"Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions","volume":"31","author":"Margolis","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib23","first-page":"748","article-title":"Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates","volume":"29","author":"Nomeir","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib24","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.clpt.2005.09.004","article-title":"In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach","volume":"78","author":"Obach","year":"2005","journal-title":"Clin. Pharmacol. Therapeut."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib25","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.105.093229","article-title":"The utility of in vitro cytochrome P450 inhibition data in the prediction of drug\u2013drug interactions","volume":"316","author":"Obach","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ddtec.2004.10.008","article-title":"Metabolic screening in vitro: metabolic stability, CYP inhibition and induction","volume":"1","author":"Riley","year":"2004","journal-title":"Drug Discov. Today: Technol."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib27","first-page":"465","article-title":"Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes","volume":"57","author":"Rodrigues","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib28","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1367-5931(00)00220-9","article-title":"Screening of drug candidates for their drug\u2013drug interaction potential","volume":"5","author":"Rodrigues","year":"2001","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib29","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ddtec.2004.10.002","article-title":"\u2018In silico\u2019 simulations to assess the \u2018in vivo\u2019 consequences of \u2018in vitro\u2019 metabolic drug\u2013drug interactions","volume":"1","author":"Rostami-Hodjegan","year":"2004","journal-title":"Drug Discov. Today: Technol."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ddtec.2004.11.009","article-title":"Automation and robotics in ADME screening","volume":"1","author":"Saunders","year":"2004","journal-title":"Drug Discov. Today: Technol."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib31","first-page":"66","article-title":"Prediction of pharmacokinetics and drug\u2013drug interactions from in vitro metabolism data","volume":"8","author":"Shou","year":"2005","journal-title":"Curr. Opin. Drug Discov. Dev."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib32","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/S0090-9556(24)13672-0","article-title":"Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates","volume":"28","author":"Stresser","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib33","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0731-7085(02)00480-6","article-title":"High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry","volume":"30","author":"Testino","year":"2003","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib34","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1124\/dmd.30.12.1441","article-title":"Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors","volume":"30","author":"Tran","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1067\/mcp.2001.116891","article-title":"Optimizing drug development: strategies to assess drug metabolism\/transporter interaction potential-toward a consensus","volume":"70","author":"Tucker","year":"2001","journal-title":"Clin. Pharmacol. Therapeut."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib36","unstructured":"Vaz, R.J., 2005. In silico model for CYP inhibition. Abstracts 37th Middle Atlantic Regional Meeting of the American Chemical Society. New Brunswick, NJ, United States, May 22\u201325, 2005, GENE-128."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib37","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1124\/dmd.32.6.647","article-title":"Validated assays for human cytochrome P450 activities","volume":"32","author":"Walsky","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib38","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0090-9556(24)15374-3","article-title":"Human cytochrome P-450 3A4: in vitro drug\u2013drug interaction patterns are substrate-dependent","volume":"28","author":"Wang","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib39","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1124\/dmd.31.7.955","article-title":"Cytochrome P450 inhibition using recombinant proteins and mass spectrometry\/multiple reaction monitoring technology in a cassette incubation","volume":"31","author":"Weaver","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpharm.2006.10.039_bib40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1570-0232(02)00548-2","article-title":"Rapid and quantitative determination of metabolites from multiple cytochrome P450 probe substrates by gradient liquid chromatography-electrospray ionization-ion trap mass spectrometry","volume":"780","author":"Zhang","year":"2002","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ijpharm.2006.10.039_bib41","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S1359-6446(05)03580-4","article-title":"High throughput P450 inhibition screens in early drug discovery","volume":"10","author":"Zlokarnik","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ijpharm.2006.10.039_bib42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1078\/0944-7113-00121","article-title":"Effects of intrinsic fluorescence and quenching on fluorescence-based screening of natural products","volume":"9","author":"Zou","year":"2002","journal-title":"Phytomedicine"}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517306009069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517306009069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T23:09:36Z","timestamp":1736636976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517306009069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":42,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0378517306009069"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2006.10.039","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}